Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 32 for:    font
Previous Study | Return to List | Next Study

Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial

This study has been completed.
Sponsor:
Collaborators:
University of Michigan
The Cleveland Clinic
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00814255
First received: December 22, 2008
Last updated: April 10, 2014
Last verified: April 2014